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Abstract
Background: Obesity is the most modifiable risk factor, and dietary induced weight loss potentially the best
nonpharmacologic intervention to prevent or to slow osteoarthritis (OA) disease progression. We are currently
conducting a study to test the hypothesis that intensive weight loss will reduce inflammation and joint loads
sufficiently to alter disease progression, either with or without exercise. This article describes the intervention,
the empirical evidence to support it, and test-retest reliability data.
Methods/Design: This is a prospective, single-blind, randomized controlled trial. The study population consists
of 450 overweight and obese (BMI = 27–40.5 kg/m2) older (age ≥ 55 yrs) adults with tibiofemoral osteoarthritis.
Participants are randomized to one of three 18-month interventions: intensive dietary restriction-plus-exercise;
exercise-only; or intensive dietary restriction-only. The primary aims are to compare the effects of these
interventions on inflammatory biomarkers and knee joint loads. Secondary aims will examine the effects of these
interventions on function, pain, and mobility; the dose response to weight loss on disease progression; if
inflammatory biomarkers and knee joint loads are mediators of the interventions; and the association between
quadriceps strength and disease progression.
Results: Test-retest reliability results indicated that the ICCs for knee joint load variables were excellent, ranging
from 0.86 – 0.98. Knee flexion/extension moments were most affected by BMI, with lower reliability with the
highest tertile of BMI. The reliability of the semi-quantitative scoring of the knee joint using MRI exceeded
previously reported results, ranging from a low of 0.66 for synovitis to a high of 0.99 for bone marrow lesion size.
Discussion: The IDEA trial has the potential to enhance our understanding of the OA disease process, refine
weight loss and exercise recommendations in this prevalent disease, and reduce the burden of disability.
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Background
Current therapy for knee osteoarthritis (OA) most often
focuses on pain relief, often with nonsteroidal anti-
inflammatory medications that have only modest func-
tional benefit, do not slow disease progression, and have
potentially serious cardiovascular and gastrointestinal
side effects [1,2]. Recent evidence also casts doubt on the
effectiveness of arthroscopic surgery for adults with mild-
to-moderate knee OA [3]. Modern approaches to OA
management should recommend targeting modifiable
risk factors, including obesity, malalignment, and muscle
weakness.
Obesity (BMI ≥ 30.0 kg/m2) is associated with increased
risk of functional impairment and is considered the most
modifiable risk factor for knee OA [4,5]. Although caloric
restriction has produced dramatic changes in many bio-
logical systems and proven beneficial to obese adults suf-
fering from knee OA, no study has directly addressed
whether intensive dietary induced weight loss also slows
the progression of structural damage in people with OA or
determined mechanistically how it happens.
Dietary weight loss is considered the best potential non-
pharmacologic intervention to prevent or to slow disease
progression [6]. Christensen et al. [7] recently found that
an 11% weight loss in older adults with knee OA over an
8-week period resulted in a 3-fold improvement in self-
reported function relative to a control group. Radio-
graphic evidence of progression was not studied in this
trial and would not be expected to change in an 8-week
period. The mechanisms responsible for improvements in
function and pain in patients with knee OA consequent to
long-term intensive dietary weight loss and exercise inter-
ventions in obese adults remain unknown. Reductions in
joint loads and inflammatory cytokines, each thought to
exacerbate joint destruction, are potential pathways. Our
current Intensive Diet and Exercise for Arthritis (IDEA)
randomized clinical trial will examine the effects intensive
weight loss has on the biomechanical and inflammatory
osteoarthritis disease pathways. We suggests that a long-
term weight loss of at least 10% of baseline body weight,
with or without exercise, will reduce knee joint loads and
decrease inflammation resulting in a slowing of disease
progression and improved clinical outcomes (Figure 1).
Recent studies demonstrate that low-grade inflammation
plays a pathophysiological role in OA. The inflammatory
cytokine interleukin-1 beta (IL-1β) is present in the joint
fluids of OA patients [8]. An inflammatory component
associated with OA can be detected in the circulation since
serum concentrations of inflammatory markers, such as
cytokines (interleukin-6, IL-6; tumor necrosis factor
alpha, TNFα) and the acute-phase reactant C-reactive pro-
tein (CRP), are higher in persons with knee or hip OA
compared to those without [9,10]. In addition, longitudi-
nal studies demonstrate that high systemic CRP and TNFα
concentrations predict increased radiographic progression
of knee OA as much as 5 years later [10,11]. Moreover, OA
severity and impaired physical function are associated
with higher inflammatory markers in the blood [12].
Thus, severity, mobility, pain, stiffness, and radiographic
progression may be partly mediated by the level of
chronic inflammation in OA patients.
Obese individuals have higher concentrations of inflam-
matory markers and may be at greater risk of functional
limitation and OA disease progression. Besides direct
effects on the joint, inflammatory mediators can affect
muscle function and sensitize nerves leading to increased
pain [13]. Studies are beginning to show that both exer-
cise training and weight loss decrease overall inflamma-
tion [14,15]. Our Arthritis, Diet, and Activity Promotion
Trial (ADAPT) showed that a dietary intervention produc-
ing a 5% weight loss significantly reduced CRP, IL-6, and
TNFα soluble receptor 1 concentrations compared to a
control group [16]. We still do not know whether there is
a "threshold" – a relative or absolute weight loss that max-
imally reduces inflammatory markers – or if improve-
ments in physical function, pain, and OA progression are
related to declines in chronic inflammation with weight
loss and exercise.
Previous studies indicate that knee OA has an adverse
effect on gait mechanics, but little is known about the
influence of obesity. Epidemiological and biomechanical
data suggest that the additional mechanical stress obesity
places on weight-bearing joints increases the propensity
for knee OA. We found that as BMI increased, older adults
with knee OA changed their gait, walking slower and
exerting greater impact forces [17]. There are no definitive
data on whether weight loss is beneficial for reducing OA
progression; however, these data support our proposed
model in which intensive dietary induced weight loss and
exercise interventions slow disease progression. This study
could make intensive dietary weight loss combined with
exercise the standard-of-care for overweight and obese
adults with knee OA and enhance our understanding of
the OA disease process and weight-loss and exercise rec-
ommendations for older people generally.
This paper describes the design of IDEA, a large scale long-
term intensive weight loss and exercise randomized clini-
cal trial, and provides new reliability data on knee joint
loads calculated using musculoskeletal modeling, and
measures of osteoarthritis disease progression using mag-
netic resonance imaging (MRI).
Methods/Design
Study Design
IDEA is a single-blinded, one center, 18-month, rand-
omized controlled trial. Participants are randomized intoBMC Musculoskeletal Disorders 2009, 10:93 http://www.biomedcentral.com/1471-2474/10/93
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one of 3 groups: exercise-only (E), intensive dietary
induced weight loss (D), or intensive dietary induced
weight loss-plus-exercise (D+E) (Table 1). Personnel
responsible for data collection are blinded to group
assignment. One-half of the participants are randomized
to supplemental testing, including MRI, strength tests,
and full-length x-rays of the lower extremities.
Study Sample
The study sample consists of 450 ambulatory, commu-
nity-dwelling persons age ≥ 55 years with: (1) grade II-III
(mild to moderate) radiographic tibiofemoral OA or tibi-
ofemoral plus patellofemoral OA of one or both knees
[18]; (2) 27.0 ≤ BMI ≤ 40.5 kg/m2; and (3) a sedentary life-
style, defined as not participating in a program that incor-
porates more than 30 minutes per week of formal exercise
within the past 6 months (Table 2). The study protocol
was reviewed and approved by the Human Subjects Com-
mittee of Wake Forest University Health Sciences.
Informed consent will be obtained from all study partici-
pants.
These criteria aim to assure that we include people who
will benefit from intensive dietary restriction [19]. By
enrolling overweight and obese people with a BMI no
greater than 40.5 kg/m2, we enhance the likelihood that
we will achieve our goal of moving each participant down
one BMI class (from Class II to Class I obesity [BMI < 35
Theoretical model by which intensive dietary restriction plus exercise decreases knee joint loads, improves strength and  power, and decreases inflammation leading to a slowing of disease progression, reduced pain, improved function, and less disa- bility Figure 1
Theoretical model by which intensive dietary restriction plus exercise decreases knee joint loads, improves 
strength and power, and decreases inflammation leading to a slowing of disease progression, reduced pain, 
improved function, and less disability.
Decreased Joint Tissue Damage Less Joint Inflammation 
Decreased PAIN
Improved Mobility 
Increased Muscular Strength Improved Body Composition 
Less Disability
Improved  Physical Function
Intensive Dietary Induced Weight Loss  ± Exercise  
for Symptomatic Knee OA  
PrimaryOutcome  Primary Outcome  Decreased Joint Loads  Decreased Pro-inflammatory
Cytokine/Adipokine Activity
Weight Loss 
Table 1: Study Design
Intensive Dietary Restriction Exercise Intensive Dietary Restriction + Exercise
N = 150 N = 150 N = 150BMC Musculoskeletal Disorders 2009, 10:93 http://www.biomedcentral.com/1471-2474/10/93
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kg/m2], Class I obesity to overweight [BMI between 27–30
kg/m2], or overweight to normal [BMI < 25 kg/m2]) [20].
Since BMI categories carry different risks for diseases and
mortality, by reducing them one full category, more pro-
found effects on disease markers may reasonably be
expected. During the study, all participants are allowed to
maintain their usual medications, including NSAIDs and
other analgesics. With their physician's consent, they can
also reduce medication if pain decreases. A detailed record
of medication use is collected at baseline and 6- and 18-
month follow-up testing.
Interventions
Intensive dietary induced weight loss intervention
Both the D and D+E groups receive the same dietary inter-
vention. Our weight loss goal is a group mean of at least
10% of baseline weight, with a desired 15% weight loss.
The dietary plan is based on partial meal replacements,
including up to 2 meal-replacement shakes per day (pro-
vided by General Nutrition Centers, Inc., Pittsburgh, PA.).
All participants are closely monitored, and their daily
caloric intake adjusted according to their rate of weight
change.
Initial diet plans provide an energy-intake deficit of 800–
1000 kcals/day as predicted by energy expenditure (esti-
mated resting metabolism × 1.2 activity factor). The low-
est calorie level permitted is 1100 kcals for women and
1200 kcals for men. The calorie distribution goal is 15–
20% from protein, < 30% from fat, and 45–60% from car-
bohydrates, consistent with the Dietary Reference Intakes
for Energy and Macronutrients [21] and successful weight-
loss programs [22]. For the third meal, participants follow
a weekly menu plan and recipes provided by the study
composed of traditional foods. It contains 500–750 kcals
and is low in fat and high in vegetables. Snacks include a
snack bar, fruit, or vegetable providing approximately
100–120 kcals each. The food plan is tailored to individ-
ual preferences and energy needs. Meal plans are devel-
oped by the intervention staff to provide the prescribed
macronutrient-balanced energy intake as fewer meal
replacements are consumed during the trial.
Body weight is monitored in weekly nutrition education
and behavioral sessions. Nutrition interventionists,
trained in behavioral therapy and experienced in working
with older adults, run all group and individual sessions.
There is one individual session and 3 group sessions per
month for the first 6 months. The behavioral sessions
focus on awareness of changing eating habits to lower
caloric intake. Information on what food changes to
make, how to make them, and why they are important is
clearly explained and discussed with participants and sig-
nificant others. Group sessions include problem solving,
review of a specific food topic, and tasting of several well-
balanced, low-fat, nutritious foods prepared with easily
available ingredients. During the individual sessions, the
nutrition interventionist reviews individual progress,
solves problems, answers questions, and sets goals. From
months 7 to 18, participants attend biweekly group ses-
sions, with an individual appointment every 2 months.
Once they reach the study's desired weight-loss goal of
15% of baseline body weight, participants either begin
Table 2: Exclusion criteria
Criteria Exclusion Method
Significant co-morbid disease that would pose a 
safety threat or impair ability to participate, 
previous acute knee injury, patellofemoral OA 
in the absence of tibiofemoral OA
Symptomatic or severe coronary artery 
disease; severe HTN; active cancer, other than 
skin cancer; anemia; dementia; liver disease; 
COPD; peripheral vascular disease; inability to 
walk without an assistive device; blindness; 
osteoporosis, ligament or cartilage damage 
from acute event; type 1 diabetes; type 2 
diabetes on thiazolidinediones agents; 
patellofemoral OA without tibiofemoral OA.
Medical history; physical exam; GXT; knee x-
ray sunrise view
Ability and willingness to modify dietary or 
exercise behaviors
Unwillingness or inability to change eating and 
physical activity habits due to environment; 
cannot speak and read English
Questionnaire, assessment by interventionists
Excess alcohol use ≥ 21 drinks per week Questionnaire
Inability to finish 18-month study or unlikely to 
be compliant
Lives > 50 miles from site or planning to leave 
area ≥ 3 months during the next 18 months
Questionnaire
Conditions that prohibit knee MRI Pacemaker, severe claustrophobia, defibrillator, 
implanted metal objects in leg, neurostimulator, 
magnetic aneurysm clip, any kind of metal 
implant or foreign metal objects in the body, 
such as bullets, shrapnel, metal slivers
Medical history
Significant cognitive impairment or depression diagnosis of dementia or a Modified Mini-
Mental State exam (3MSE) score < 70, CES-D 
score > 17
Medical history, 3MSE, CES-DBMC Musculoskeletal Disorders 2009, 10:93 http://www.biomedcentral.com/1471-2474/10/93
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weight maintenance or continue to lose weight using safe,
healthy nutritional practices. Weight loss can continue
throughout the intervention, provided the individual
wants to and has not reached a level that may be associ-
ated with health hazards in this population; i.e., a >20%
body weight loss at 6 months or > 30% at 12 months.
Weight maintenance uses relapse-prevention techniques
that include managing the environment, adjusting appro-
priate goal-based daily energy needs, and continuing self-
regulatory skills.
For participants who have difficulty achieving the weight-
loss goal, we use a behavioral "toolbox" that includes fre-
quent individual behavioral counseling sessions, incen-
tives, home-assessments, or other items deemed
appropriate. Diet plans can be altered to restrict one of the
snacks and/or the size of the evening meal. Participants
record their food and beverage intake in daily logs that are
collected monthly and used as a self-monitoring tool for
dietary intake. Nutrition interventionists use them to
design rescue procedures, using behavioral and educa-
tional strategies.
Alert Values
Weight is monitored weekly. A loss of >20% body weight
after 6 months or >30% after 12 months triggers a safety
alert.
Exercise intervention
The exercise intervention is identical for both exercise
groups. Sixty-minute sessions are conducted 3 d·wk-1 for
18 months, and each group (E and D+E) exercises at a dif-
ferent time to prevent crossover effects from their interac-
tions. The first 6 months are facility-based. Anytime after
6-month follow-up testing is completed, participants that
would like to add home based exercise to their training
routine will alternate between the facility (2 d·wk-1) and
home (1 d·wk-1) during a 2-week transition phase. Subse-
quently, participants can decide to remain in the facility
program; opt for a home-based program; or combine the
facility and home-based programs.
The 3 d·wk-1 exercise program consists of an aerobic
phase (15 min), a strength training phase (20 min), a sec-
ond aerobic phase (15 min), and a cool-down phase (10
min). The strength-training phase is particularly relevant
to help offset any possible loss of muscle and bone mass
resulting from dietary weight loss.
Walking is the primary mode of aerobic training. Partici-
pants who meet the inclusion criteria but cannot walk for
extended periods use upright and recumbent stationary
bicycles to supplement walking. Exercise intensity ranges
between 50–75% of the heart-rate reserve, using the
symptom-limited maximum heart rate obtained from a
graded exercise test (GXT). The strength training session is
approximately 20 minutes and targets lower extremity
muscles and, to a lesser extent, upper body muscles. This
phase includes 1–2 sets of 10–12 repetitions on leg exten-
sion, leg press, seated leg curl, seated calf raise, compound
row, and vertical chest or incline press.
During months 7–18, home-based participants are tele-
phoned every other week in the first 2 months, every third
week during the next 2 months, and every month thereaf-
ter. Monthly exercise and attendance logs are gathered to
monitor progress. The home-based participant exercises at
home 3 d·wk-1 and comes to the facility once a month for
an individual meeting with the exercise interventionist.
Home-based strength training utilizes a Thera-Band exer-
cise program.
Intensive dietary induced weight loss-plus-exercise intervention
Participants randomized to the D+E intervention receive
both interventions described above. Dietary counseling is
scheduled before or after the exercise sessions to minimize
the number of visits.
Techniques to Improve Adherence
We conservatively estimate 80% retention and 65%
adherence rates over this 18-month intervention. Adher-
ence to the nutrition intervention is defined as attending
the nutrition classes; to the exercise sessions, the number
of sessions completed divided by the number scheduled
(72 weeks × 3 d·wk-1 = 216 sessions).
The health psychologist trains the exercise interventionists
in behavioral techniques that include: (1) tailoring train-
ing to the participant's ability; (2) frequent contact during
all intervention phases; (3) clear behavioral goals and
feedback on achievements; (4) training participants to
self-monitor their heart rate and to complete activity logs;
(5) establishing personal commitment to the project
through the exercise leader; and (6) targeting educational
materials and field trips to prevent relapse and to develop
prompts to exercise. Primary interventionists regularly
review adherence data and identify any participants who
need additional reminders and/or counseling.
Trial Conduct
Recruitment
The 30-month recruitment period is divided into 10
waves of 45 participants each, entering the study at 3-
month intervals. Recruitment strategies include mass
mailings, newspaper advertisements, and presentations at
local aging service networks, senior centers, and churches.
Our Claude D. Pepper Older Americans Independence
Center recruitment core also has access to a large database
of older adults who have consented to be contacted about
participation in clinical trials. Selected physicians inBMC Musculoskeletal Disorders 2009, 10:93 http://www.biomedcentral.com/1471-2474/10/93
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orthopedics, geriatrics, and rheumatology receive infor-
mation on the study and encourage qualified patients to
contact IDEA recruitment personnel for further informa-
tion. Specific strategies aim to maximize the number of
African Americans who qualify for, and are enrolled in,
the study. At biweekly meetings, all recruitment activities
and the number of participants randomized are reviewed.
Screening (SV) and follow-up (FU) visits
Figure 2 shows eligibility and screening measurements for
the IDEA trial. All participants are tested at baseline and 6
and 18 months post randomization. A subset of 225 par-
ticipants receive supplemental performance tests, x-ray,
and MRI (Figure 2).
Measurements
Screening measurements
The Eligibility Questionnaire addresses joint pain, physi-
cal function, activity level, co-morbid diseases, willing-
ness to participate in an 18-month study, height and
weight (to determine BMI), caregiver status, status of sig-
nificant others, and distance of home from the center
(within a 50-mile radius). Demographic information
includes data on occupation, income, and education. The
medical form is used to determine co-morbidities and to
analyze medication data gathered by self-report. A com-
puterized system places individual drugs in major thera-
peutic categories to assess changes in nonsteroidal anti-
inflammatory drug use. Participants undergo an initial
symptom-limited, maximum exercise stress test to exclude
anyone who has severe manifestations of coronary heart
disease using a modified Naughton protocol that has 10
stages. Volunteers are screened for cognitive deficiencies
using the Modified Mini-Mental State Exam (3MSE) [23].
A score of < 70 justifies exclusion because we feel that cog-
nitively impaired persons could not adhere to the proto-
col, especially the dietary requirements for the weight-loss
groups.
Inflammatory Markers
We plan to assess biological markers of inflammation
before and after weight-loss and exercise treatments to
determine whether they significantly lower inflammation
levels. Our primary measure is IL-6. This cytokine is con-
sistently implicated in OA pathogenesis and showed sig-
nificant improvement with weight loss in ADAPT. We will
also measure CRP as an overall marker of chronic inflam-
mation [10] and TNFα and TNFα soluble receptor 1
(sTNFR1) because these cytokines are also implicated in
OA pathogenesis [24]. Leptin, an adipokine that increases
synthesis of TGFβ, a known stimulator of osteophyte for-
mation, is also measured.
Blood and Urine Sample Collection
Blood samples (approximately 40 ml per visit) for assess-
ing biomarkers are collected via venipuncture in the early
morning, after a 12-hour fast and at baseline, 6-month,
and 18-month assessment visits. Urine samples (20 ml
per visit) are collected in 250 ml specimen cups by each
participant for analysis of new and emerging OA biomar-
kers. In the event of acute respiratory, urinary tract, or
other infection, we postpone blood and urine sampling
for 1–2 weeks after recovery from symptoms.
Gait Analysis
Our primary measures of knee joint loads are tibiofemoral
compressive forces and the internal abduction moment.
We obtain 3-D kinematic gait data using a 25-reflective
marker set, arranged in the Cleveland Clinic configura-
tion, a 6-camera Motion Analysis System sampling at 60
Hz and EVaRT 4.4 software. Ground reaction forces and
moments are obtained with a 6-channel force platform
(Advanced Mechanical Technologies, Inc., Newton, MA)
operating at 480 Hz. Six successful trials are collected on
each participant, and 3 chosen for subsequent analysis. A
successful trial is defined as one in which the participant's
entire foot is placed on the surface area of the force plat-
form while walking within ± 3.5% of freely chosen speed.
A Butterworth low-pass filter with a 6 Hz cut-off frequency
is used to remove high frequency noise from the linear
kinematic data. OrthoTrak 6.0 β4 clinical gait analysis
software is used to generate lower extremity angular kine-
matic and kinetic data using inverse dynamics. Knee-joint
forces are calculated using a model developed by DeVita
et al[25,26]. We have successfully applied it to healthy
and OA subjects[25,26], finding ranges (2.8 – 6.0 BW)
similar to those in previous studies [27,28].
Test-retest reliability and the effect of BMI
The reliability of the gait data was determined using 21
IDEA participants (4 males, 17 females) with a mean age
of 65.7 ± 5.8 yrs, a mean mass 92.4 ± 13.0 kg, and a mean
height of 165.6 ± 10.0 cm. Participants were tested twice,
1 week apart. Intra-class correlation coefficients (ICC)
were used to compare the between day reliability of peak
internal knee flexion/extension and internal knee abduc-
tion/adduction moments, peak knee compressive force,
peak vertical ground reaction force, and stride length.
Overall day-to-day reliability was excellent with ICC val-
ues ranging from 0.86–0.98 for the selected variables
(Table 3). Knee flexion/extension moment and stride
length were most affected by BMI, with lower reliability
associated with the highest tertile of BMI (Table 3 and Fig-
ure 3).
Western Ontario McMasters Universities Osteoarthritis Index 
(WOMAC)
The WOMAC is used to measure self-reported physical
function and pain [29]. The LK version asks participants
to indicate on a scale from 0 (none) to 4 (extreme) the
degree of difficulty experienced performing activities ofBMC Musculoskeletal Disorders 2009, 10:93 http://www.biomedcentral.com/1471-2474/10/93
Page 7 of 14
(page number not for citation purposes)
Participant eligibility and screening Figure 2
Participant eligibility and screening.
Telephone Interview: Eligibility Status, Medical History 
Consent, Medication Form, Ht, Wt, Brief Phys Exam 
Pass ? 
Pass ?  Pass ? 
OA 
KL=2-3 
27 ≤ BMI ≤ 40.5  GXT 
Knee X-Ray 
3MSE > 70 
Questionnaires 
WOMAC 
SF36 
DEMO 
PASE 
Adherence 
Satisfaction with life 
PANAS 
Falls Questionnaire 
Walking Efficiency 
Gait efficiency 
FAST 23 
ABC 
Waist-Hip Ratio 
6 min walk 
Gait analysis 
Randomization 
Blood Draw 
DXA 
Diet Analysis 
Urine collection 
MRI 
Strength 
Full-length lower 
extremity x-ray 
Exclude or 
override 
Exclude 
Exclude 
Exclude or 
override 
Prescreen 
Exclude 
Screening Visit 1 
Screening Visit 2 
Randomization Visit 
50% randomized to 
additional testing 
yes yes
yes
yes
yes
no
no 
no
no
no 
yesBMC Musculoskeletal Disorders 2009, 10:93 http://www.biomedcentral.com/1471-2474/10/93
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daily living in the last 48 hours due to knee OA. Individ-
ual scores for the 17 items are totaled to generate a sum-
mary score that can range from 0–68, with higher scores
indicating poorer function.
The pain index assesses participants' pain on the same
scale, ranging from 0 (none) to 4 (extreme). The pain sub-
scale consists of 5 items and total scores can range from 0–
20, with higher scores indicating greater pain. This instru-
ment is recommended by the Osteoarthritis Research
Society as the health status measure of choice for older
adults with knee OA. It has been validated for use in
orthopaedic and pharmacologic interventions [29,30].
Mobility
Our mobility measure is 6-minute walk distance. Partici-
pants are told to walk as far as possible in 6 minutes on an
established flat, indoor course. Six-minute walk distance
is related to symptom-limited maximal oxygen consump-
tion (r = 0.53) and the test has a 3-month test-retest relia-
bility of 0.86 [31].
Body Composition
Body mass index is calculated as mass (measured in kilo-
grams on a standard calibrated scale) divided by height
squared (measured in meters). Whole body lean mass
(LM), fat mass (FM), and bone mass are measured by DXA
on all 450 participants. BMD is also measured at the pos-
teroanterior (PA) lumbar spine and hip. DXA scans are
obtained with a fan-beam scanner, Delphi A™, Hologic
(Waltham, MA), using manufacturer's recommendations
for patient positioning, scan protocols, and scan analysis.
Coefficients of variation (%CV) are 1.2% for whole body
FM; 0.5% for whole body LM; 0.9% for whole body BMD;
1.2% for PA spine BMD; and 0.9% for total hip BMD.
Strength
We measure bilateral knee concentric strength at baseline,
FU6, and FU18 on a random sample of participants (n =
225) with equal numbers in each group using a Kin-Com
125E isokinetic dynamometer set at an angular velocity of
30 deg/sec. Grip strength, an excellent measure of overall
body strength, is also measured using a standard grip
strength dynamometer.
Medications
During SV1 and FU visits, participants are administered a
medication questionnaire adapted from the Atherosclero-
sis Risk In Communities (ARIC) study [32] and widely
used in field research and our prior studies. We obtain
information about all prescription and over-the-counter
medicines and supplements used during the 2 weeks prior
to the interview.
MRI
MRI of the most symptomatic knee will be performed at
baseline and FU18. MRI scans are performed with 1.5
Tesla General Electric scanners using an extremity coil.
The following MR sequences were obtained: (1) Double
oblique coronal three-dimensional spoiled gradient echo
(SPGR) with fat suppression; (2) Axial T1-weighted spin-
echo (SE); (3) Double oblique coronal T1-weighted SE;
(4) Sagittal T1-weighted SE; (5) Sagittal T2-weighted fast
spin echo (FSE) with fat suppression; (6) Double oblique
coronal T2-weighted fast spin echo (FSE) with fat suppres-
sion.
Semi-quantitative scoring of whole joint
MRI has the capability of visualizing all potentially rele-
vant OA joint structures; therefore, it is not surprising that
it is an important tool in improving our understanding of
knee OA by providing a non-invasive tool for the study of
healthy and diseased states, as well as in providing a
means of assessing risk factors for and the effectiveness of
therapeutic interventions for prevention of pain, dysfunc-
tion, and disability in OA. MRI scoring will be read paired
and blinded to timepoint by a musculoskeletal radiologist
using the BLOKS method [33]. The following MRI features
are scored: (1) Bone marrow lesion (BML) size; (2) BML
% area; (3) Percent BML rather than cyst; (4) Cartilage
loss; (5) Extent of any cartilage loss at specified points;(6)
Test-retest reliability for knee joint loads calculated during  gait Figure 3
Test-retest reliability for knee joint loads calculated 
during gait. (A) Knee flexion/extension moment with an 
ICC = 0.86, and (B) Knee compressive forces with an ICC = 
0.95.
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Osteophytes; (7) Synovitis; (8) Effusion; (9) Meniscal
extrusion; (10) Meniscal signal; (11) Meniscus tear; (12)
Ligaments: presence or absence of tear in patella tendon,
ACL or PCL; and (13) Periarticular features: presence or
absence of abnormal features such as pes anserine bursa
and iliotibial band.
Test-retest reliability was performed on 10% of scans (N =
22) 1 week apart. Prior data demonstrates the inter-reader
reliability for the BLOKS items range from 0.51 for menis-
cal extrusion up to 0.79 for meniscal tear. The reliability
for other key features is 0.72 for BML grade, 0.72 for carti-
lage morphology, and 0.62 for synovitis [33]. Our reliabil-
ity exceeded previously reported results (Table 4).
Reliability for meniscal extrusion was 0.95; meniscal tear,
0.99; BML size, 0.72, cartilage morphology, 0.93, and syn-
ovitis 0.66.
Quantitative Cartilage Morphometry
Measurements are confined to the medial femorotibial
compartment, because (1) it is the most common site of
knee OA [34]; (2) OA there is strongly related to bone
marrow edema lesions and varus knee alignment [34,35];
and (3) we have additional, well-established measures of
joint integrity using BLOKS [33]. The tibia (MT) and cen-
tral weight-bearing medial femur (cMF) are segmented by
manually tracing of the total area of the subchondral bone
(tAB) and the area of the cartilaginous joint surface (AC)
on a slice-by-slice basis [36,37]. Segmentation of tAB
included all areas of cartilage-covered and denuded
subchondral bone, but not osteophytes [36,37]. Likewise,
AC segmentation excluded osteophyte cartilage. MT was
segmented throughout all slices that displayed cartilage;
analysis of the femoral condyle was confined to the por-
tion of the condyles that is displayed without relevant par-
tial volume effect in coronal images (cMF). All segmented
data are quality controlled (QC'd) by one expert by check-
ing all segmented slices of each data set, and corrections
of the segmentation were performed if necessary (Figures
4 &5).
The same software used for segmentation and QC read-
ings is used to calculate the size of the total area of the
subchondral bone (tAB), the tAB covered with cartilage
(cAB), the denuded bone area (dAB), the area of the carti-
lage surface (AC), the mean cartilage thickness across the
entire tAB (ThCtAB), counting all denuded areas as 0 mm
cartilage thickness the mean cartilage thickness across cAB
(ThCcAB), and maximal cartilage thickness. In addition,
subregional measurements are performed by analyzing
ThCtAB in central, internal, external, anterior and poste-
rior subregions of MT, and central internal and external
subregions of cMF, using a recently developed approach
by Wirth et al. [38]. Figure 6 represents a 3-D visualization
of the segmented data.
Health-Related Quality of Life
The SF-36 [39] is the most widely used and carefully vali-
dated measure of HRQL. It yields two broad summary
scores: physical health and mental health.
X-ray
To assess lower limb alignment, a full-length anteroposte-
rior radiograph (AP) of each lower extremity is obtained
at baseline on a random sample (n = 225) with equal
numbers in each group. Subjects are positioned following
the methods of Sharma et al. [40]. Alignment is defined as
the measure of the angle formed by the intersection of the
line connecting the centers of the femoral head and inter-
condylar notch and connecting the centers of the ankle
talus and tibial spines. A varus knee is an angle > 0° in the
inward direction, and valgus is an angle > 0° in the out-
ward direction.
Bilateral, anterior-posterior, weight-bearing knee x-rays
are used to identify tibiofemoral arthritis, and sunrise
views to identify patellofemoral OA. Anterior-posterior x-
rays are repeated at FU18 to assess changes in joint-space
width and Kellgren and Lawrence (K-L) score. MRI is sen-
sitive in detecting changes in joint structure and is the pri-
mary measure for progression in this trial. X-rays are
evaluated because (1) current regulatory guidance recom-
mend them as the gold standard for measuring disease
progression http://www.fda.gov/BiologicsBloodVaccines/
GuidanceComplianceRegulatoryInformation/
default.htm; and (2) obtaining plain films of both knees
to monitor disease progression bilaterally is straightfor-
ward.
Table 3: Test-retest reliability (ICC) of selected gait variables for all subjects (n = 21) and in tertiles of BMI (kg/m2)
Gait variable All Subjects 34 < BMI ≤ 41 32 ≤ BMI ≤ 34 27 ≤ BMI < 32
Knee Extensor Moment 0.86 0.80 0.72 0.94
Knee Abductor Moment 0.94 0.95 0.97 0.86
Knee Compressive Force 0.95 0.90 0.95 0.98
Vertical GRF 0.98 0.92 0.95 0.99
Stride length 0.95 0.69 0.97 0.99BMC Musculoskeletal Disorders 2009, 10:93 http://www.biomedcentral.com/1471-2474/10/93
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Participants' knees are flexed at 15 degrees using a posi-
tioning device, and the beam centered on the joint space.
The x-ray beam is directed perpendicular to the cassette to
pass between the femoral condyles and the patella sur-
faces. The exact angle of the beam depends upon the
degree of flexion of the knee and the participant's individ-
ual body habitus. The focus-to-film distance is held con-
stant throughout the study. This method of acquisition
standardizes positioning to optimize reproducibility [41]
but may not afford the same responsiveness of fluoro-
scopic methods of acquisition [42]. A single physician,
masked to the treatment group, will read the radiographs.
Severity of tibiofemoral OA is measured using the K-L
grading scale and defined as present if K&L grade is ≥ 2
[18]. The minimum joint-space width of both compart-
ments is measured using a 0.1 mm graduated magnifying
lens to assess disease progression
Modified Mini-Mental State Exam (3MSE)
The 3MSE is an objective, quantitative assessment of cog-
nitive functioning that examines orientation to time and
place, recall, short-term memory, and arithmetic ability.
Participants scoring below 70 are not eligible for the
study.
Physical Activity Scale for the Elderly (PASE)
The PASE scale, used to estimate activity levels, has proven
reliable in many of our clinical trials [43].
Accelerometry
Physical activity monitoring is also performed using accel-
erometry on the same random sample of 225 participants.
Participants are provided a Lifecorder EX uniaxial acceler-
ometer at baseline, 6, and 18-month follow-up and asked
to wear it for 7 consecutive days. It measures step counts,
daily energy expenditure, physical activity patterns, and
daily activity energy expenditure.
Dietary Assessment
Dietary intake will be assessed at our General Clinical
Research Center (GCRC) by registered dietitians who are
not involved in the intervention. Participants complete a
3-day food record at baseline, 6, and 18 months, which is
analyzed for nutrients using the accurate, standardized,
and comprehensive Minnesota Nutrition Data System
(NDS). Portion sizes are estimated using 2D food-portion
visuals available from NDS and discussed with the partic-
ipant at baseline.
2.4.19. Body weight, height, BMI, waist circumference
Body weight, height, and waist circumference are
obtained at baseline, 6, and 18 months using standard
techniques. The range of BMIs for inclusion is 27.0 to 40.5
kg/m2.
Statistical Considerations
Statistical Analyses
All primary analyses will be based on the intention-to-
treat method in which each participant is included in the
initial randomization group regardless of adherence.
IDEA stratification factors, BMI, and gender will be
included in all statistical models, so the analysis will
match the design, and the estimated variance will not be
biased. Assumptions will be verified for all models, and
appropriate transformations used when necessary.
Primary Aim
The primary aim of this study is to test whether the inten-
sive dietary intervention, the exercise-only intervention,
and a combination affect inflammation (IL-6) and knee
joint loads (knee maximum compressive force) differ-
ently. Analyses for the primary aim will test the effect of
the 3 interventions on the primary outcome measures
using repeated measures analysis of covariance
(ANCOVA). These methods are robust-to-moderate
departures from linearity when the covariates are not
extremely different. Eighteen months after randomiza-
tion, intervention effects will be estimated and tested,
adjusting for prerandomization levels, BMI, and gender.
Subsequent models will be adjusted for other variables,
including age, education, long-term individual prefer-
ences for exercise, and specific factors showing group dif-
ferences at baseline.
Secondary Aims
The effect of the interventions on WOMAC function and
pain; inflammation markers, including CRP, TNF-α, TNF-
sR1, and leptin; and maximal internal abduction moment
will be determined with repeated measures ANCOVA and
statistical tests and estimates as described above, verifying
assumptions and using appropriate transformations. We
will examine whether increased weight loss slows disease
progression and how changes in the biomechanical and
Table 4: Intra-observer reliability for reading of MRI BLOKS 
features (weighted kappa)
BLOKS feature Reliability
(weighted kappa)
BML size 0.72
BML % area 0.67
% of lesion BML 0.79
Cartilage 1 morphology 0.95
Cartilage 2 0.93
Osteophyte 0.74
Synovitis 0.66
Effusion 0.77
Meniscal extrusion 0.95
Meniscus tear/cysts 0.99
BLOKS = Boston Leeds Osteoarthritis Knee Score
BML = Bone Marrow LesionBMC Musculoskeletal Disorders 2009, 10:93 http://www.biomedcentral.com/1471-2474/10/93
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inflammatory pathways result in improved function,
diminished pain, and slower disease progression. Multi-
variate and multiple regression methods will be used to
study the associations between factors in the hypothe-
sized pathway.
Sample size calculations
A total sample size of 450 (150/group) provides 80% sta-
tistical power to detect 20% differences in IL-6 and 15%
differences in knee joint loads at the two-sided 0.008 sig-
nificance level (adjusted for 3 pairwise intervention com-
parisons and 2 outcomes) with 80% retention. Our
preliminary data suggest that a 20% difference in IL-6 is
clinically important, and an additional 5% weight loss for
a 200 lb patient would result in a 120 lb difference in knee
joint loads. Estimates of mean squared error were
obtained from the ADAPT study [44], which measured the
same outcomes and used a similar patient population.
Based on the assumptions above and the evaluation of
secondary outcomes, the trial is designed to ensure that
120 subjects per group are evaluated at the end of 18
months.
Discussion
Finding interventions that will slow or stop disease pro-
gression is a critical area of OA research. Pharmacologic
and surgical interventions have had limited success
[3,45], and nonpharmacologic interventions, such as
exercise and dietary induced weight loss, improve self-
reported physical function and pain but appear to result
in similar disease progression rates as attention control
groups [44,46]. Modest weight loss is a recommended
treatment for knee OA [47]; however, a 5% weight loss,
alone or in combination with exercise, does not attenuate
disease progression [44]. IDEA is the first adequately pow-
ered, long-term trial to examine whether more intensive
weight loss, with or without exercise, will reduce inflam-
mation and knee joint loads sufficient to alter disease pro-
gression.
Weaknesses of the study include the challenges involved
in losing and then maintaining significant weight loss,
and the lack of a gold-standard biomechanical model to
estimate knee joint loads. Our previous work suggests that
long-term intensive weight loss is required to affect the
OA disease process. However, achieving long-term weight
loss in obese individuals is challenging. Interventions last-
ing longer than 1 year that attain at least a 10% weight loss
are rare. Esposito et al. [22] produced a 14.7% loss in
body weight over a 2-year period in women following a
moderate energy restricted diet (1300 kcals year 1 and
1500 kcals year 2). We will incorporate partial meal
replacements, frequent contacts, and an intensive behav-
ioral intervention that emphasizes self-regulatory skills
and relapse prevention.
Musculoskeletal models only provide estimates of actual
knee joint biomechanics. The principal limitation of our
model is the absence of most knee ligaments. This will
increase knee-muscle force predictions, since these tissues
must resist all external loads. The model does include the
lateral collateral ligament, which produces the principal
non-muscular restraint during the stance phase of walk-
ing. We have successfully applied it to healthy and OA
subjects [25,26,48], finding ranges similar to those of pre-
vious studies [27,28].
Baseline double oblique coronal MR image acquired using a  fat suppressed SPGR sequence with a 1.5 mm slice thickness  and 0.31 mm × 0.31 mm in plane resolution Figure 4
Baseline double oblique coronal MR image acquired 
using a fat suppressed SPGR sequence with a 1.5 mm 
slice thickness and 0.31 mm × 0.31 mm in plane reso-
lution. The area of the cartilage surface (AC) and the total 
subchondral bone area (tAB) are manually segmented in the 
medial tibia (MT) and weight-bearing medial femur (cMF). 
The part of the tAB covered by AC is defined as the cartilag-
inous area of bone (cAB), that not covered by the AC as the 
denuded area of bone (dAB).
AC
MT LT
cLF cMF
cAB dAB
tABBMC Musculoskeletal Disorders 2009, 10:93 http://www.biomedcentral.com/1471-2474/10/93
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In addition to the benefit and feasibility of intensive
weight loss in this population, IDEA will elucidate the
benefits of exercise, both with and without intensive
weight loss, on knee joint loads, stability, and neuromus-
cular function. The Osteoarthritis Research Society Inter-
national (OARSI) has strongly recommended exercise as
part of the standard of care for patients with knee OA [49].
Our previous work indicated that long-term exercise
improves walking mechanics and reduces knee pain
[46,50]; however, to our knowledge, no studies have
examined the effects of exercise on knee joint loads in this
population. Data from animal models suggest that the
magnitude and direction of the applied loads influence
whether knee articular cartilage responds favorably to reg-
ular exercise [51]. Using qMRI, IDEA will determine in
vivo the relationship between knee joint loads and carti-
lage thickness changes. MRI may also detect effects of
weight loss and exercise on OA progression because it is
more sensitive to change than traditional radiographs.
Knee alignment is a known risk factor for disease progres-
sion [40]. Several authors have suggested that obesity
exacerbates disease progression only in the presence of
mild varus knee alignment [34]. As a secondary outcome,
we will examine baseline knee alignment to determine its
influence on 18-month disease progression using both
semi-quantitative (BLOKS) and quantitative MRI (qMRI).
The IDEA trial has substantial potential to enhance our
understanding of the OA disease process, refine weight-
loss and exercise recommendations in this prevalent dis-
ease, and to ultimately reduce the burden of disability in
our aging population. This study could make intensive
weight loss with exercise the standard-of-care for over-
weight and obese adults with knee OA, as it enhances our
3D visualization of the femorotibial subregions: Top: anterior  view with the medial tibia being divided into 5 subregions  (red = central, green = external, dark blue = internal, yellow  = posterior, and turquoise = anterior subregion Figure 6
3D visualization of the femorotibial subregions: Top: 
anterior view with the medial tibia being divided into 
5 subregions (red = central, green = external, dark 
blue = internal, yellow = posterior, and turquoise = 
anterior subregion. The central subregion is defined by a 
cylinder and occupies 20% of the total subchondral bone area 
of medial tibia (MT). The weight bearing femur is divided into 
three strip-like subregions, each occupying 33.3% of the 
subchondral bone area (green = central, dark blue = internal, 
red = external subregion). The total subchondral bone area 
of the lateral tibia is shown in green and that of the lateral 
femur in red. Middle: oblique anterior-superior view of the 
subregions. Bottom: superior view onto the tibial subregions 
(femur not shown).
Flow chart visualizing the image analysis and quality control  (QC process) Figure 5
Flow chart visualizing the image analysis and quality 
control (QC process).
MR image acquisition:
 Double oblique coronal SPGR sequence 
with water excitation
QC of MR image acquisition: 
Anatomical coverage
Orientation
Fat-suppression
Motion
Other artefacts
MR image segmentation:
(Trained Readers) 
 Track AC and tAB
 Segment MT and cMF
QC of segmentation:
(Automated) 
 Contour labels correctly assigned
 Cartilage label correctly assigned
(checked by distance to fibula)
 Same number of slices in 
baseline and follow up data set
QC of segmentation: 
(Expert Reader)
 Contours correctly placed
First and last slice in each 
cartilage correctly placed
Osteophytes eliminated
Contact zone correctly defined
Computation of global and 
regional cartilage  morphology: 
VC, tAB, AC, cAB, dAB, 
ThCtAB, ThCcaB, regional ThCtAB
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understanding of the OA disease process and weight-loss
and exercise recommendations for older people generally.
Moreover, the use of MR imaging may increase our capa-
bility to detect effects of weight-loss and exercise on OA
progression because of its higher sensitivity to change
compared with x-ray.
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